bukhaly
عضو نشط
- التسجيل
- 21 يناير 2003
- المشاركات
- 763
خبر فرش
Lifeline Biotechnologies Pursues Prospective Major Breakthrough in Breast Cancer Detection
via COMTEX
March 20, 2007
RENO, Nev., Mar 20, 2007 (BUSINESS WIRE) --
Lifeline Biotechnologies, Inc. (OTCPK: LBTN) today announced that it is nearing a major breakthrough in the early detection of breast cancer. The new experimental classifying algorithms, the basis for Lifeline's First Warning System(TM), demonstrate sensitivity of 100% (the ability to find lesions in the breast) and two additional algorithms documented a specificity (the ability to distinguish benign from cancerous lesions) of 84% and 91% with its new neural network system which is nearing ready for clinical testing on large patient data sets.
Louis Keith, MD, PhD, Lifeline's Medical Director, stated, "For several decades medical researchers have struggled to find an accurate method for using the interpretation of thermal circadian data related to tumor growth in the breast as a detection modality. Many researchers believe the thermal data code of the breast's minute incremental temperatures changes are direct reflections of the breast's physiological activity and tumor growth."
Dr. Keith went on to say, "One in five women with breast cancer die of the disease; early detection is extremely important and should be the point of reference in evaluating any screening program. Past studies have shown that the characteristics of rhythmic changes in skin temperature of clinically healthy cancerous breasts are real and measurable. The superficial thermal patterns measured on the surface of the breast are related to tissue metabolism and vascularization within the underlying tissue. Cancer development appears to generate its own thermal signatures, and the complexity or lack thereof may be a reflection of its degree of development."
According to Lifeline's CEO, Jim Holmes, "These physiological phenomena led to the initial research in the mid-1980s by Lifeline's founder Dr. William Reeves and resulted in the development of prototype computer microprocessors capable of capturing these thermal aberrations as well as the development of the 'First Warning System(TM)' and ultimate patent protection of the technology and software."
About Lifeline Biotechnologies
SAFE HARBOR: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.
SOURCE: Lifeline Biotechnologies, Inc.
Lifeline Biotechnologies, Inc. Investor Relations Rodney Marvel, 866-THE-APPLE www.lbtn.com
Lifeline Biotechnologies Pursues Prospective Major Breakthrough in Breast Cancer Detection
via COMTEX
March 20, 2007
RENO, Nev., Mar 20, 2007 (BUSINESS WIRE) --
Lifeline Biotechnologies, Inc. (OTCPK: LBTN) today announced that it is nearing a major breakthrough in the early detection of breast cancer. The new experimental classifying algorithms, the basis for Lifeline's First Warning System(TM), demonstrate sensitivity of 100% (the ability to find lesions in the breast) and two additional algorithms documented a specificity (the ability to distinguish benign from cancerous lesions) of 84% and 91% with its new neural network system which is nearing ready for clinical testing on large patient data sets.
Louis Keith, MD, PhD, Lifeline's Medical Director, stated, "For several decades medical researchers have struggled to find an accurate method for using the interpretation of thermal circadian data related to tumor growth in the breast as a detection modality. Many researchers believe the thermal data code of the breast's minute incremental temperatures changes are direct reflections of the breast's physiological activity and tumor growth."
Dr. Keith went on to say, "One in five women with breast cancer die of the disease; early detection is extremely important and should be the point of reference in evaluating any screening program. Past studies have shown that the characteristics of rhythmic changes in skin temperature of clinically healthy cancerous breasts are real and measurable. The superficial thermal patterns measured on the surface of the breast are related to tissue metabolism and vascularization within the underlying tissue. Cancer development appears to generate its own thermal signatures, and the complexity or lack thereof may be a reflection of its degree of development."
According to Lifeline's CEO, Jim Holmes, "These physiological phenomena led to the initial research in the mid-1980s by Lifeline's founder Dr. William Reeves and resulted in the development of prototype computer microprocessors capable of capturing these thermal aberrations as well as the development of the 'First Warning System(TM)' and ultimate patent protection of the technology and software."
About Lifeline Biotechnologies
SAFE HARBOR: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.
SOURCE: Lifeline Biotechnologies, Inc.
Lifeline Biotechnologies, Inc. Investor Relations Rodney Marvel, 866-THE-APPLE www.lbtn.com
